Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

RECRUITING

NCT07227298

PHASE1/PHASE2

Sponsor: Pfizer

Summary

This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery or cured with standard treatments. To join in the study, participants must: * Be 18 years or older * Participants with advanced non-small cell lung cancer (NSCLC), a type of lung cancer that has spread The study will look at: * Whether PF-08634404 is safe to use with other cancer medicines. * What side effects may happen. A side effect is anything the medicine does to your body that is not part of treating your disease. * Whether the combination of PF-08634404 and other cancer medicines can help treat solid tumors. The study has different parts, each testing PF-08634404 with a different cancer medicine: * Part A will test PF-08634404 with a medicine called sigvotatug vedotin. * Part B of the study will look at how well the new medicine PF-08634404 works when used together with another medicine. Participants will receive the study medicines through an intravenous (IV) infusion (injected into the vein) at the study clinic. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.

Official title: AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

162

Start Date

2026-01-30

Completion Date

2033-08-23

Last Updated

2026-07-08

Healthy Volunteers

No

Conditions

Advanced/Metastatic Non-Small Cell Lung Cancer Carcinoma, Non-Small Cell Lung Non-Small Cell Lung Cancer

Interventions

BIOLOGICAL

PF-08634404

-Concentrate for solution for infusion

BIOLOGICAL

Sigvotatug Vedotin

-Powder for concentrate for solution for infusion. Single use vial

BIOLOGICAL

Combination Agent 1

-Powder for concentrate for solution for infusion. Single use vial.

Locations (55)

Highlands Oncology Group, PA

Fayetteville, Arkansas, United States

Highlands Oncology Group, PA

Rogers, Arkansas, United States

Highlands Oncology Group, PA

Springdale, Arkansas, United States

Providence Medical Foundation

Fullerton, California, United States

Providence St. Jude Medical Center - Virginia K. Crosson Cancer Center and Infusion Center

Fullerton, California, United States

Providence St. Jude Medical Center

Fullerton, California, United States

Rocky Mountain Cancer Centers, LLP

Denver, Colorado, United States

BRCR Medical Center Inc.

Coral Springs, Florida, United States

Mid Florida Hematology and Oncology Center

Orange City, Florida, United States

Orlando Health Ambulatory Care Center

Orlando, Florida, United States

Orlando Health Cancer Institute

Orlando, Florida, United States

Orlando Health Orlando Regional Medical Center

Orlando, Florida, United States

BRCR Global - Tamarac

Tamarac, Florida, United States

Montefiore Medical Center- Montefiore Medical Park

The Bronx, New York, United States

Oncology Associates of Oregon, P.C.

Eugene, Oregon, United States

Dallas Cancer Specialists

Garland, Texas, United States

Southwest Oncology Associates

Houston, Texas, United States

Lumi Research

Houston, Texas, United States

US Oncology Investigational Products Center (IPC)

Irving, Texas, United States

Voyage Clinical

Sugar Land, Texas, United States

VCU Medical Center Gateway Building